Surveillance of Rare Adverse Events Post-Vaccination
Surveillance of Rare Adverse Events Post-Vaccination Surveillance of Rare Adverse Events Post-Vaccination Why rare-event surveillance matters—and what a regulator expects to see Licensure is not the end of safety work; it marks the start of population-scale learning. Pre-licensure studies are typically underpowered for events occurring at 1–10 per million doses (e.g., anaphylaxis, myocarditis, thrombosis with…
Read More “Surveillance of Rare Adverse Events Post-Vaccination” »